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A number of mechanisms have been elucidated that maintain neuropathic pain due to spinal cord injury (SCI). While target-
based therapeutics are being developed based on elucidation of these mechanisms, treatment for neuropathic SCI pain has not
been entirely satisfactory due in part to the signiﬁcant convergence of neurological and inﬂammatory processes that maintain the
neuropathic pain state. Thus, a combination drug treatment strategy, wherein several pain-related mechanism are simultaneously
engaged, could be more eﬃcacious than treatment against individual mechanisms alone. Also, by engaging several targets at once,
it may be possible to reduce the doses of the individual drugs, thereby minimizing the potential for adverse side eﬀects. Positive
preclinical and clinical studies have demonstrated improved eﬃcacy of combination drug treatment over single drug treatment
in neuropathic pain of peripheral origin, and perhaps such combinations could be utilized for neuropathic SCI pain. At the same
time, there are mechanisms that distinguish SCI from peripheral neuropathic pain, so novel combination therapies will be needed.
1.Introduction
Tissue injury or disease may lead to a persistent pain state.
Chronic pain is maintained through a combination of neural
and nonneural mechanisms operating simultaneously at
peripheral and central nervous systems [1, 2]. At the site
of peripheral tissue damage, a number of inﬂammatory
mediatorsarereleasedthatactivateandrecruitimmunecells,
initiating the process of tissue repair. Also, many of these
mediators released from recruited immune cells, including
excitatory amino acids, neuropeptides, and cytokines, sensi-
tize primary aﬀerent nociceptors [3–5]. The persistent pain
state could be maintained, in part, by the overproduction
of these mediators and by the overexpression by genes of
cell membrane-bound proteins, such as receptors and ion
channels, and intracellular signaling complexes in peripheral
nerves [6–8]. Furthermore, the physiological responses of
spinal dorsal horn neurons and primary aﬀerent neurons are
permanently altered, such that their responses to peripheral,
cutaneous stimulation are exaggerated and persist long after
the application of stimulation. These physiological changes
are believed to be maintained by long-lasting changes in
genes and, akin to the process observed in peripheral noci-
ceptors, overexpression of membrane-bound proteins and
overactivation of intracellular signaling [9, 10].
Spontaneous activity has been demonstrated from
injured peripheral sensory neurons and from CNS neurons,
proximally and distally to the site of injury [11–13]. The
abnormal neurophysiological responses to peripheral injury,
sensitization, and spontaneous activity are believed to be
the neural basis of tissue injury-induced chronic pain,
which is characterized by cutaneous hypersensitivity and
spontaneous pain.
In spinal cord injury (SCI), spontaneously active CNS
neurons, found spinally and supraspinally, have been doc-
umented in both clinical and experimental settings [14–20].
Experimental evidence suggests that reducing the activity of
these neurons leads to a decrease in chronic pain symptoms.
Drugs that have demonstrated to decrease CNS neural
activity, including opioids, γ-aminobutyric acid (GABA)
receptor agonists, and sodium channel blocking drugs, are
antinociceptive in animal pain models and these drugs are2 Pain Research and Treatment
also analgesic in clinical pain states [21]. The data suggest
that robust pain relief can be obtained though suppressing
abnormal neural activity. Obtaining direct evidence, such as
electrophysiological and neurochemical, of drug eﬀects from
patients as performed in animals, is a tremendous technical
hurdle. However, noninvasive imaging may be an alternate
method to quantify drug eﬀects on brain neurochemistry
and activity and these data could correlate with pain relief
[22, 23]. Furthermore, such data could be used to guide drug
discovery.
The existence of multiple, often overlapping mechanisms
that have been identiﬁed so far not only underscores the
biological complexity of chronic pain, but the diﬃcultly
in providing signiﬁcant pain relief with currently available
analgesic pharmacotherapies. The vast array of pain-related
mechanisms, however, invites development of a nearly
endless list of potential treatments, especially treatments that
target more than one mechanism.
2. Combination Therapy: Synergism
One could take advantage of the parallel activities of
molecular targets by engaging several of these targets at once,
wherein the goal is a combination treatment that is superior
to that of individual target-speciﬁc treatments [24, 25]. The
concept of synergism has been demonstrated in the clinical
setting for a variety of indications such as the treatment
of cancer and infections [26]. Combining drugs may lead
to either additive or non-additive eﬀects. If the eﬀect of a
combination of two or more drugs does not signiﬁcantly
deviate from the theoretical or expected eﬀect based on
their individual dose-response curves, then the eﬀect of the
combination is said to be additive. There are two types of
nonadditive eﬀects that may result with combination treat-
ment. First, if the eﬀect of the combination is greater than
expected,thenthecombinationissaidtobesuperadditive,or
synergistic. The total dose of the synergistic combination can
be lower than what would be expected from the individual
dose-response curves, which may also diminish the risk of
adverse side eﬀects associated with either drug. Secondly, the
total dose needed to induce a certain eﬀect may be higher
than what is expected. In this case, the combination is said
to be subadditive or antagonistic.
The key is that the experimentally derived result be
statistically signiﬁcant from the expected result. One method
to determine this is by isobolographic analysis, wherein the
doses of the constituents that give, for example, a 50%
antinociceptive eﬀect, are plotted on the x-axis and y-axis
[26, 27]. The line connecting these points is said to be the
“line of additivity,” a locus of dose pairs of the constituents
expected to demonstrate equal antinociception (“zero inter-
action”).Theamountofeachconstituentinthecombination
can be based on the relative potency of the constituents. Fol-
lowing construction of a dose-response curve of the combi-
nation, the 50% antinociceptive dose is determined and sta-
tistical analysis is used to determine whether or not the eﬀect
of the combination signiﬁcantly deviates from zero interac-
tion, whether the eﬀect of the combination is either synergis-
tic, antagonistic, or merely additive. While one ratio of the
constituents may be merely additive, other ratios may lead to
either synergistic or antagonistic eﬀects [28]. Thus, the lack
of synergy for a given combination should not automatically
exclude that combination from further consideration—
perhaps other combination ratios could lead to synergy.
There are cases of synergism in which one of the drugs in
a two-drug combination demonstrates no eﬃcacy [29]. To
demonstrate synergism, a statistically signiﬁcant increase in
the potency of the active drug of the combination compared
to the active drug alone is required. Thus, drugs that do not
demonstrate eﬃcacy on their own may still be useful when
given with drugs that do demonstrate eﬃcacy [30–32]. The
advantage of this type of combination is similar to that of a
combination in which both drugs demonstrate eﬃcacy—the
dose of the eﬃcacious drug in the combination is decreased
thereby reducing the potential for adverse side eﬀects.
3. Neuropathic SpinalCord InjuryPain
In the U.S., there are an estimated 256,000 SCI patients and
there are approximately 12,000 new cases of SCI each year,
most commonly due to motor vehicle accidents and falls
[33]. As medical breakthroughs increase life expectancy in
general, there will be a growing population of elderly, and
life expectance of current SCI patients could increase as well.
In addition, with increasing numbers of older persons, it is
anticipated that they may develop SCI, due to, for example,
accidents [34, 35]. Older SCI, as well as non-SCI, patients
are more likely than younger people to report chronic pain
[36]. Thus, with the signiﬁcant expansion of the elderly
population in the U.S. and other industrialized countries
projected by midcentury and the potential for an increased
number of elderly SCI patients, there is an urgent need to
develop eﬀective pain therapeutics [37, 38].
In addition to signiﬁcant losses in motor and visceral
functionalities, intractable pain may also result following
SCI, a majority of SCI patients reporting the severity of
pain as either moderate or severe, such that there is greatly
diminished mood and motivation to participate in rehabili-
tation programs and social interaction [39–41]. Pain may be
localized in dermatomes either above, at, or below the level
of injury [42–44]. Interestingly, below-level pain has been
described as “burning” or “shooting” and accompanied by
cutaneous hypersensitivity, symptoms that are characteristic
of peripheral neuropathic pain [44, 45]. There is also the
possibility of “autonomic dysreﬂexia,” a condition in which
noxioussomaticorvisceralstimulationbelowthelevelofSCI
could lead to an acute, uncontrolled sympathetic nervous
system response, including a life-threatening increase in
blood pressure and tachycardia [46]. Thus, treatments that
are tolerated in other pain populations may not be suitable
for SCI patients. For example, visceral distention by opioids
and antidepressants such as amitriptyline could lead to
autonomic dysreﬂexia.
Furthermore, treatments that are eﬃcacious in periph-
eralneuropathicpaindonotappeartodemonstratethesame
level of eﬃcacy in neuropathic SCI pain. Amitriptyline, for
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such as urinary retention, does not appear to be as eﬀective
in neuropathic SCI pain as it is in peripheral neuropathic
pain[47].Mexiletine,anorallyactiveanalogueofthesodium
channel blocking drug lidocaine, also does not show the level
of eﬃcacy in SCI patients that has been demonstrated in
peripheral neuropathic pain patients [48, 49]. Perhaps the
lack of eﬃcacy across patient populations could be due in
part to varied testing protocols and outcome measurements
intheclinicaltrials,butsomeofthediﬀerentialeﬃcacycould
also be due to underlying diﬀerences in pain mechanism.
If standard pharmacotherapies, when given alone, do not
demonstrate eﬃcacy, then combination drug therapy could
be a viable option for SCI pain patients.
4. PreclinicalCombination Drug
Therapy in the SCI Rat
To facilitate the evaluation of novel pharmacotherapies for
potential clinical use, a rat model of chronic neuropathic
SCI pain was recently developed [50, 51]. Four weeks
following a brief midthoracic spinal compression, a massive
inﬁltration of monocytes and a robust gliotic response
were observed at the injury site. In addition, syrinxes were
observed extending for several segments from the injury
site. The histopathological ﬁndings are reminiscent of that
reported following an acute spinal contusion, a widely used
method of inducing SCI in rats, and in clinical SCI [52,
53]. Despite signiﬁcant bilateral motor dysfunction below
the level of the injury, similar in degree and extent to
that following a contusion injury, rats were responsive to
cutaneous stimulation. The methods of quantifying below-
level cutaneous hypersensitivity used were the same as those
commonly used in rat models of peripheral nerve injury [54,
55]. A long-lasting below-level hypersensitivity to cutaneous
stimuli, as observed in clinical SCI pain, was obtained
beginning one week following spinal compression, which
lasted for at least 12 weeks after-injury [56].
A variety of clinically used analgesic drug were assessed
in these rats. The anxiolytic drug diazepam did not demon-
strate antinociceptive eﬃcacy, indicating that sedative or
muscle relaxant property is not suﬃcient to ameliorate pain-
related behaviors [57, 58]. While mexiletine and the anti-
convulsant drug carbamazepine were found to be eﬃcacious
in other chronic pain models, these did not demonstrate
signiﬁcanteﬀectsinSCIrats[59,60].Theanti-inﬂammatory
cyclooxygenase-2 selective inhibitor rofecoxib and the non-
selective cyclooxygenase inhibitor naproxen also did not
aﬀect below-level cutaneous hypersensitivity, suggesting that
prostaglandins are not a critical factor in maintaining the
neuropathic state in these rats [61]. The doses of rofecoxib
and naproxen tested in SCI rats were eﬃcacious, however,
in rat models of inﬂammation-induced pain. The lack of
eﬃcacy of several analgesics in SCI rats compared to other
rat pain models suggests fundamental diﬀerences in mecha-
nisms among the chronic pain states.
At the same time, several drugs that demonstrated
antinociception in peripheral neuropathic pain models also
demonstrated eﬃcacy in the current SCI model, suggesting
that both peripheral and SCI pain share a few common
mechanisms. Clinical drugs that are generally characterized
as selective for a particular target, including opiates, the
GABAB receptor agonist baclofen, the voltage-gated calcium
channel (VGCC) blocker gabapentin, and noncompetitive
N-methyl-D-aspartate(NMDA)receptorantagonistssuchas
ketamine, showed eﬃcacyin both models of SCI and periph-
eral nerve injury pain [60, 62–66]. The analgesic tramadol
also demonstrated eﬃcacy in both SCI and peripheral neu-
ropathic pain models [66–69]. Interestingly, the eﬃcacy of
tramadol is likely to be mediated by a combination of several
mechanisms: its metabolite is a μ-opioid receptor agonist
and the drug itself increases synaptic levels of analgesic
neurotransmittersserotoninandnorepinephrinebyblocking
the reuptake of these neurotransmitters [69]. Both separate
and simultaneous activation of rat spinal cord dorsal horn μ-
opioid and serotonergic receptors and α-adrenoceptors leads
to marked antinociception in acute pain tests [70, 71]. Since
drugs are usually dosed systemically, antinociceptive eﬀects
could be the result of engaging pain-related targets in several
sites within the CNS and those targets may also be found in
peripheral nerves [72–74]. Given the presence of a number
of pain-related mechanisms involved in modulating pain
perception, there are potentially numerous combinations
that may lead to synergistic analgesia [75].
Some of the common side eﬀects observed with analgesic
drugs with systemic bioavailability include somnolence,
sedation, dizziness, and nausea [41]. Adverse side eﬀects
are inevitable since most currently available analgesics freely
distribute throughout the CNS. With combination drug
therapy, it may be possible to signiﬁcantly reduce the inci-
denceofsideeﬀectsbyreducingthedosesoftheconstituents.
Alternatively, there are drug delivery methods which may
further minimize the incidence of side eﬀects. One method
is to deliver drugs into the intrathecal (i.t.) space of the
spinal cord [76]. Some analgesics that demonstrated eﬃcacy
when given systemically also demonstrated robust eﬃcacy
following i.t. injection in SCI rats, indicating that the spinal
dorsal horn is a key site of action of these drugs [77–79].
In rats with a spinal hemisection, blockade of spinal NMDA
receptors at the site of spinal injury with i.t. injection of the
competitive NMDA receptor antagonist AP-5 ameliorated
below-level hypersensitivity to innocuous mechanical stim-
ulation (but not injury-induced heat hypersensitivity) [80].
The eﬀects of clinically used NMDA receptor antagonists,
such as ketamine or memantine, were not evaluated in
these rats. While block of dorsal horn NMDA receptors in
general leads to an antinociceptive eﬀect in chronic pain
models, it appears that the degree of eﬃcacy depends on
whether the antagonist used is a competitive or noncom-
petitive antagonist [81, 82]. In-house data indicates that i.t.
ketamine, at doses that do not induce hind limb dysfunction,
does not ameliorate below-level cutaneous hypersensitivity
inratswithaspinalcompressioninjury.Incontrast,systemic
NMDA receptor antagonist treatment is eﬀective, suggesting
that supraspinal NMDA receptors have a prominent role in
maintaining below-level cutaneous hypersensitivity in spinal
compression-injured rats [50]. The main disadvantage of
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in doses that lead to signiﬁcant supraspinally mediated psy-
chomimetic eﬀects and those that lead to antinociception
[83]. Even though i.t. ketamine alone was not eﬃcacious, as
noted earlier, it could be eﬀective if combined with other i.t.
delivered analgesic drugs.
A number of combination therapies have been evaluated
for eﬃcacy in preclinical models of neuropathic pain but few
have been tested speciﬁcally in a preclinical model of neu-
ropathic SCI pain and so their potential clinical usefulness is
unknown [24].Becauseofpossible diﬀerences in mechanism
between peripheral and SCI pain states, combinations that
maybe useful in one state might not show eﬃcacy in the
other state. Therefore, it will be crucial to test potential com-
bination drug therapies in models of SCI pain.
Recently, a number of drug combination therapies have
been evaluated for antinociceptive eﬃcacy in rats with spinal
compression injury. While baclofen is approved for use in
spasticity, it has been used oﬀ label for the treatment of
neuropathic pain, including neuropathic SCI pain [84, 85].
Because systemic dosing can lead to side eﬀects such as
sedation and muscle weakness, i.t. baclofen has been utilized
as a means of long-term pain treatment. However, pharmac-
ological tolerance to the beneﬁcial eﬀect of i.t. baclofen
has been reported, and potentially dangerous withdrawal
symptoms may occur if i.t. infusion is suddenly interrupted
[86–88]. One method of reducing the dose of baclofen and
reducing the possibility of tolerance and the severity of with-
drawal is to combine it with other drugs. Preliminary data
from SCI rats indicates that i.t. injection of a combination
of ketamine and a 50% eﬃcacious dose of baclofen leads
to a signiﬁcant enhancement of baclofen antinociception
(unpublished data). The combination also underscores a
mechanistic hypothesis, that chronic SCI pain is maintained
by a simultaneous decrease in GABAergic inhibition and
increase in NMDA receptor-mediated excitation [80, 89, 90].
Therefore, considerable pain relief could be obtained by
blockingtheNMDAreceptorandactivatingGABAreceptors.
While ketamine was synergistic with baclofen, combina-
tion i.t. treatment of GABAA receptor agonist muscimol
and ketamine did not lead to synergism. That there was
synergism with GABAB, but not with GABAA,r e c e p t o r si s
puzzling. The lack of synergism could be explained via a
paradoxical in vitro ﬁnding that activation of the GABAA
receptor leads to the activation of NMDA receptors [91].
Thus, there is the need for further elaboration of possible
interactions between pain-related targets in order to ﬁnd
useful combinations for clinical eﬃcacy. Given all of the
potential interactions within the pain transmission system,
it appears that synergism is a novel occurrence at best [29].
Ziconotide, a synthetic analogue of a peptide derived
from the marine snail Conus magnus, is prescribed for use as
an i.t. monotherapeutic for severe chronic pain [92]. Preclin-
ical and limited clinical studies indicate that ziconotide may
beusefulinbelow-levelSCIpain[93,94].Ziconotideactsvia
blockade of the N-type VGCC, which are expressed on cen-
tral terminals of primary aﬀerent nociceptors, which synapse
with dorsal horn spinal neurons [95]. Blocking spinal N-
type VGCCs prevents an inﬂux of calcium ions and the
subsequent increase in intracellular calcium concentration,
thereby preventing the calcium-mediated release of neu-
rotransmitter from central terminals and transmission of
nociceptive signaling across the synapse. N-type VGCC
found on spinal neurons are also blocked by ziconotide,
thereby reducing nociceptive signaling within the CNS.
Furthermore, N-type VGCCs in the “neuropathic state”
appears to be more sensitive to ziconotide block compared
to N-type channels from uninjured animals, since treatment
with ziconotide does not aﬀect nociception in uninjured
animals [96, 97]. There are reports of psychiatric eﬀects
with i.t. ziconotide treatment, which are ameliorated when
the dose is lowered, indicating that the side eﬀects are
target mediated [98]. Another naturally derived peptide,
conantokin-G, blocks NMDA receptors, with an antinoci-
ceptive eﬀect similar to that of small molecule NMDA
receptor antagonists [99]. Interestingly, i.t. treatment with
conantokin-G in rats does not lead to the characteristic
side eﬀects typically observed with small molecule NMDA
receptor antagonists, so this peptide could ﬁnd potential use
as a monotherapeutic. Nonetheless, the i.t. combination of
ziconotide and conantokin-G leads to a synergistic antinoci-
ception in SCI rat, whereas the combination of the two
leads to additive antinociception in other rat pain models
[93]. Why synergism of this combination is observed in SCI
compared to other injury states is not entirely clear at this
point. There are a number of naturally derived substances,
other than peptides, that block ion channels and receptors
which may confer signiﬁcant clinical analgesia alone and
which may also signiﬁcantly enhance the analgesic eﬃcacy
of currently available drugs [100, 101].
Cannabinoids have been used for hundreds, if not thou-
sands, of years as a therapeutic for a variety of conditions,
including pain [102]. Cannabinoid (CB) receptor agonists
have demonstrated robust antinociceptive eﬀects in a variety
of preclinical models of chronic pain [103, 104]. Activation
of CB receptors alone and in combination with other recep-
tors involved in nociceptive processing leads to synergistic
antinociception in rodent pain models [105–107]. There
are varying degrees of eﬃcacy of CB receptor ligands in a
numberofclinicalpainstates,althoughtheyarenotasrobust
as reported in preclinical studies [108]. The mixed levels of
clinical eﬃcacy could be due in part to pharmacokinetics.
Eﬃcacy has been reported with inhaled CB receptor ligands
but not for orally ingested CB receptor ligands in central
pain states [49, 109, 110]. A problem that arises from
systemic delivery of CB receptor agonists is activation of
both spinal and supraspinal receptors, which not only leads
to antinociception but also signiﬁcant psychomotor eﬀects
[111]. Given the strong psychomotor side eﬀects observed
with therapeutic doses of CB1 receptor agonist, and the
sociopolitical controversy surrounding the use of this class of
drug for medical use in general, alternative means by which
to engage CB receptors for pain relief are needed.
One method to indirectly engage CB receptors would be
to increase synaptic concentrations of endogenous cannabi-
noid receptor ligands (or “endocannabinoids”), such as
anandamide (N-arachidonoylethanolamide), by inhibiting
the enzyme which degrades it, fatty acid amide hydrolase
(FAAH). Other enzymes involved in metabolizing otherPain Research and Treatment 5
endocannabionods could also be utilized as pain targets
[112]. Antinociceptive eﬀects have been demonstrated by
increasing CNS anandamide with FAAH inhibitors in pre-
clinical models of neuropathic and inﬂammatory pain,
and the eﬀects were CB receptor dependent [113–115].
Furthermore, the antinociceptive eﬀects were not accompa-
nied by the adverse side eﬀects commonly observed with
eﬃcacious doses of small molecule CB receptor agonists.
Development of selective and potent FAAH inhibitors for
clinical use is currently on-going. However, a metabolite
of the over-the-counter drug acetaminophen (acetyl-para-
aminophenol), AM404, has been shown to increase synaptic
levels of anandamide by blocking the neuronal reuptake of
anandamide [116]. Acetaminophen itself acts through var-
ious mechanisms and these mechanisms in total, including
its eﬀect on synaptic endocannabinoid levels, could explain
its analgesic eﬀects [117]. Acetaminophen is safe when taken
as directed, and has a long clinical history, either alone
or as a combination therapeutic [118, 119]. Until recently,
acetaminophen-based combination drug therapy has not
been evaluated in SCI pain models [120]. Acetaminophen
alone did not alter below-level cutaneous hypersensitivity,
even at doses that demonstrated eﬃcacy in other pain
models. However, combining acetaminophen with a 50%
eﬃcacious dose of gabapentin signiﬁcantly increased the
eﬃcacy of gabapentin. In addition, the antinociception was
attenuated with treatment of the CB1 receptor antagonist
rimonabant but not the CB2 receptor antagonist AM630,
indicating that the combination antinociceptive eﬀect is
mediated through endocannabinoids activating CB1 recep-
tors (the antinociceptive eﬀect of gabapentin alone was not
blockedwithpretreatmentofrimonabant).Thecombination
of acetaminophen with morphine was also synergistic and
partially mediated by CB1 receptors. Not all acetaminophen
combinations demonstrated synergism, however, as combi-
nationwitheithermemantineortramadolweremerelyaddi-
tive. These results suggest that acetaminophen combinations
could be useful in clinical SCI pain by combining indirect
CBreceptoractivationwithmodulationofotherpain-related
targets. In addition, increasing endocannabinoids could be a
method to circumvent the use of potent CB receptor agonists
which lead to supraspinally mediated side eﬀects.In practice,
there may be a period of trail and error in determining an
optimal combination that will lead to synergism in humans.
Potentially useful combinations are not always available
in convenient oral formulation and this may hamper patient
compliance. The possibilities of adverse drug interactions
and,fori.t.administration,tissuetoxicityneedtobecarefully
considered. As a potential alternative to pharmacotherapeu-
tics,transplantationofcellsthatreleaseamixtureofanalgesic
substances could be a long-term means to reduce neuro-
pathic SCI pain. A number of studies have demonstrated
that adrenal medullary chromaﬃn cells, which release cat-
echolamines, opioid peptides, other neuropeptides includ-
ing the NMDA receptor antagonist histogranin, and neu-
rotrophic factors, implanted in the spinal subarachnoid
lumbar space, lead to signiﬁcant antinociception in various
animal models of pain [121, 122]. Because of the diﬃculty
of obtaining cadaver adrenal medullary tissue for human
implantation, cell lines have been engineered to secrete anal-
gesic neurotransmitters, such as GABA and serotonin [123].
The genes for neuroactive peptides, such as ziconotide and
histogranin, could be inserted into the genome of these
cells [124, 125]. Thus, a mixture of substances would be
continuously released into the CSF to ameliorate pain on
a long-term basis, without the need for maintenance or
reﬁllingthereservoirofani.t.druginfusionpump.Anadded
advantage is that these mixtures could be designed to reduce
the potential for analgesic tolerance. The addition of NMDA
receptor antagonists, for example, appears to delay or inhibit
theonsetoftolerancetotheantinociceptiveeﬀectsofopioids
that emerges over time when they are given alone in animals
[126].
5. ClinicalUse of Combination Drug
Therapy in SCI Pain
The preclinical data suggests that clinically used drugs in
combination could be useful in ameliorating SCI pain. Even
drugs that do not demonstrate eﬃcacy alone could still be
useful if combined with a drug that is known to oﬀer pain
relief. While the preclinical data are indeed promising, few
clinical studies have been performed and fewer still have
demonstratedanalgesicsynergismontheorderofmagnitude
observed in preclinical studies. Ideally, the demonstration
of synergism should be carried out with methodological
rigor similar to that performed in preclinical studies, such as
generationofdose-eﬀectcurvesoftheconstituentsaloneand
ad o s e - e ﬀect curve of the combination, the proportion of the
constituents of the combination determined by the individ-
ual curves. Also, each drug alone and in combination would
be compared with a placebo treatment group [25, 127]. The
presence of genuine synergism is further complicated by the
fact that few, if any, studies suspend analgesic usage prior to
thecommencementofthestudy,suchthatthesupra-additive
eﬀect of the drugs under investigation could be due to
nonstudy medications. Given the limited number of suitable
clinical subjects and ethical reasons, analgesic synergism
studies are few and far between. Nonetheless, a few carefully
designed studies have demonstrated synergism in the clinical
setting. One study demonstrated a synergistic interaction
between i.t. morphine and clonidine, an α2-adrenoceptor
agonist, in SCI patients [128]. Doses of i.t. morphine and
clonidine were titrated in each patient until either eﬃcacy
or side eﬀects was obtained. A 50% eﬃcacious dose of
each drug was calculated, then given as a mixture, which
yielded analgesia greater than either drug alone and equally
analgesic in SCI patients with either at-level or below-level
neuropathic pain.
Other studies evaluated the eﬀect of a second therapeutic
as an “add-on,” wherein the second drug is added to an
already existing drug treatment. For example, i.t. morphine
was evaluated as an add-on in SCI patients who were under-
going treatment with a stabilized dose of i.t. baclofen for
pain and spasticity [129]. Although most of the patients who
received add-on i.t. morphine tolerated the combination, the
average reduction in pain was modest, about 35%. A case6 Pain Research and Treatment
report noted improved pain and spasm relief in a SCI
patient with clonidine added to i.t. baclofen [130]. Prior
to the addition of clonidine, the patient found it necessary
to escalate the dose of baclofen needed for pain relief over
time. Two years following the initiation of the combination
therapy, no further increase in the dose of baclofen was
necessary. Ziconotide has also been used as an add-on to
i.t. baclofen (and, alternatively, baclofen as an add-on to i.t.
ziconotide) and in combination with i.t. hydromorphone, an
opioid [94, 131].
One novel combination evaluated in neuropathic SCI
pain patients was i.v. ketamine (given once a day for seven
days)asanadd-ontooralgabapentin,comparedtoi.v.saline
treatment and oral gabapentin (300mg TID) [132]. During
the week of i.v. treatment, the ketamine add-on group
showed markedly lower average pain scores compared to the
saline-treated group. Furthermore, the group that received
i.v. ketamine continued to show reductions in pain scores for
at least two weeks after the last infusion of ketamine. After
this period, the pain scores of the ketamine-treated group
were similar to that of the saline-treated group. This study
also demonstrated two interesting eﬀects of oral gabapentin
treatmentinSCIpatients.First,inbothgroups,painscoresat
the end of the study (ﬁve weeks in duration) were reduced to
about half that of baseline, pretreatment pain scores. Thus,
the study conﬁrmed the persistent analgesia obtained with
regular gabapentin treatment in SCI patients [41]. Second,
in the i.v. saline-treated group, a signiﬁcant analgesic eﬀect
with oral gabapentin treatment can be discerned on the ﬁrst
day of treatment, and analgesia improved over the course
of gabapentin treatment. An acute analgesic eﬀect of oral
gabapentin has also been reported in clinical peripheral
neuropathic pain, reducing both spontaneous pain and cuta-
neous hypersensitivity within hours of treatment [133]. The
mechanism of the two-week analgesic enhancement follow-
ing ketamine treatment is unknown. It is possible that other
combinations with gabapentin may lead to an enhanced and
persistent analgesia.
Dose-dependent eﬀects of the add-on drug or the on-
going therapeutic were not established in these studies. Per-
haps the eﬀect of the combinations was derived mainly from
the add-on drug rather than the combination per se. Clearly,
furtherstudiesareneededtodetermineifthesecombinations
fulﬁll the deﬁnition of synergism and what the optimal
drug ratio would be, but concurrent activation of spinal
GABAB receptors with either N-type VGCC block, μ-opioid
receptor,orα2-adrenoceptoractivationcouldbeapotentially
therapeutic combination. Currently, the only drugs that are
approved by the U.S. Food and Drug Administration for
i.t. in humans are ziconotide, morphine, and baclofen, and
no recommendation has been issued regarding the mixture
of these drugs for intrathecal use [134]. Furthermore, the
safety of other unapproved drugs for i.t. use has not been
extensively determined.
While it may be relatively straightforward for some SCI
patients to take medications orally, other patients may have
diﬃculty swallowing. In the case where i.t. drug delivery
may not also be an option, topical drug application may be
warranted. At-level neuropathic SCI pain is hypothesized to
result from the sensitization of primary aﬀerent nociceptors
due to the trauma that led to SCI [42]. Alternatively,
centrally mediated processes resulting from SCI feedback
onto central terminals of nociceptors, which in turn leads to
nociceptor sensitization [135]. Activation of nociceptors in
some SCI patients with topical capsaicin leads to increased
hypersensitivity to cutaneous stimulation and a burning
painful sensation [136]. This indicates that not only are at-
level nociceptors intact, but normal functionality has been
signiﬁcantly altered. Application of lidocaine patches in the
painful dermatome reduces spontaneous and evoked pain.
Other topical treatments have been tested in peripheral
neuropathic pain and perhaps these could be used, either
alone or in combination, for at-level neuropathic SCI pain
[137–139]. It is not known if topical treatment would be
eﬀective on below-level SCI pain. A signiﬁcant peripheral
contribution to SCI pain suggests that targeting nociceptors
could be an eﬀective treatment and that the drug (or com-
bination of drugs) does not have to enter the CNS, thereby
circumventing the problem of CNS-mediated adverse side
eﬀects [74, 140, 141].
The contribution of peripheral nociceptors in neuro-
pathic SCI pain, however, could vary between patients.
A clinical report was unable to demonstrate a change of
peripheral nociceptor responsiveness to capsaicin treatment,
either at, below, or above the lesion, in SCI patients [142].
This result suggests that in some patients, central processes,
rather than functional changes in peripheral nociceptors,
maintain neuropathic SCI pain. Thus, treatments that focus
on attenuating the abnormal neural activity at spinal and
supraspinal levels would beneﬁt these patients. Perhaps a
topical capsaicin test could be used to assess peripheral
nociceptor functionality and based on the result, tailor
treatment for that patient. A pressing challenge for health
care providers will be to identify the relevant mechanism
in each SCI patient such that therapeutic intervention will
address those particular mechanism and yield pain relief.
6. Other Possible Combination Treatments
One other instance of synergy demonstrated in animals,
which may not have immediate clinical applicability, is
injectionofadrugatdiﬀerentsitesoftheneuraxis[143,144].
Such “autosynergy” suggests an interaction of two or more
neural sites are required for the analgesic eﬀect of a given
drug and that loss or dysfunction of one site will result in
decreasedeﬃcacyofthatdrug.Thisconceptcouldbeapplied
to the use of electrical stimulators implanted in CNS regions
involved in nociceptive processing [145]. Neither deep brain
stimulation nor spinal cord (dorsal column) stimulation
in SCI patients have demonstrated eﬃcacy on pain, but
perhaps the combination of the two, spinal and supraspinal
or into distinct but complementary brain nuclei, could lead
to robust analgesia [146, 147]. Furthermore, drugs, either
systemic or i.t., could also be combined with stimulators, to
enhance the eﬀect of the stimulator or vice versa [148, 149].
Thus, the application of synergism may not be limited to
pharmacotherapeutics.Pain Research and Treatment 7
7. Conclusion
Combination drug therapy could fulﬁll current needs in at
least two areas. It is foreseen that noteworthy new treatments
will emerge in the near future with the increased elucidation
of the mechanism that underlies neuropathic SCI pain.
However, the discovery process involving novel therapeutic
targets is both expensive and highly time consuming, and
that the safety of treatments based on those targets will not
be clearuntil the completion of extensive human trials [150].
Untilthedaywhennoveltreatmentsarereadyforwidespread
use, patients could be treated with currently available
pharmacotherapieswithknownbiologicalandsafetyproﬁles
in novel combinations. Soon-to-be-initiated clinical studies
will evaluate the suitability of cellular transplants to repair
SCI and to promote functional recovery. However, there is
the possibility that transplantation will induce sprouting of
aﬀerent central terminals, such that SCI patients who have
not experienced pain may begin to experience it or that on-
going pain in other patients will worsen [151–154]. Again,
combination drug therapy could be used as these patients
undergo transplantation treatment.
There are challenges that will need to be addressed with
combination drug therapy for SCI pain, similar to the chal-
lenges noted for other patient populations, including timing
of drug dosing and dose ratio [25]. Currently, the emergence
and submergence of particular pain-related mechanisms
over time are not well delineated, and it is assumed that
many of the processes occur all at once. Aging may alter
the temporal aspect of pain mechanisms which could in
turn alter responsiveness to therapeutics [155–158]. Perhaps
greater eﬃcacy and safety could be obtained if drugs are
combined at deﬁned times during the course of treatment.
With greater understanding of the temporal aspects of pain
mechanisms, irrelevant drugs can be excluded depending on
the duration of the pain symptoms. As mentioned earlier,
the ratio of constituents in a combination could also change,
depending on the prevalence or robustness of a particular
mechanism [65, 68]. Thus, greater understanding of post-
injury mechanism timing will be needed.
Finally, although animal models have been useful in
elaborating the in vivo neurological and biochemical mech-
anisms of pain, one limitation is the diﬃculty of obtaining
spontaneous or unevoked measures of pain. As pain involves
an aﬀective as well as sensory component, the eﬀect of novel
analgesicsonthiscomponentiscurrentlyunknown,andmay
be as therapeutically important as reducing the somatosen-
sorycomponentofpain.Itisclearthatbelow-levelcutaneous
stimulation in rats leads to pain-related behaviors such as
vocalization and licking and biting of the stimulated area,
indicating a supraspinally mediated component [159, 160].
In fact, such an overlap, between cutaneous hypersensitivity
and below-level pain in SCI patients is clinically observed
[56]. Given the signiﬁcant contribution of supraspinal
structures, including cortical structures, in pain, models of
integrated, “purposeful” behaviors in animal pain models
have been proposed [161–163]. There are neuroanatomical
and cognitive issues that will need to be addressed in tying
complex behavior in nonhuman species to human behavior,
which should be made clear when drawing conclusions from
such behavioral models [164–166]. As with other preclinical
models, the responses to pharmacological manipulation, to
both analgesics and nonanalgesics (as “active placebos”),
will need to be elaborated. Testing in alternate species and
evaluating spontaneous behavior could also prove highly
useful in closing the gap between laboratory proof-of-
concept and utilizing discoveries in the clinic [167].
8. Summary
The beneﬁts of combination drug therapy for the treatment
of neuropathic SCI pain include potential analgesic syner-
gism, wherein the eﬃcacy of the combination is signiﬁcantly
greater than that of the constituents alone and deceased
potential for adverse side eﬀects. Recent advances in the neu-
rosciences have uncovered numerous pain-related molecular
targets. However, neuropathic SCI pain remains diﬃcult to
treat with available pharmacotherapeutics since they do not
speciﬁcally address neuropathic SCI pain. Engaging more
than one relevant target via combination drug therapy may
signiﬁcantly improve pain management in SCI patients.
Further clinical studies will be needed to address key issues
suchasidentifyingwhichtargetcombinationscouldyieldthe
most robust eﬃcacy and the optimal dose ratio of a given
combination drug therapy.
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